about
Clinical use of cobicistat as a pharmacoenhancer of human immunodeficiency virus therapyImmune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-1-infected patients.Sequential population pharmacokinetic modeling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategiesPharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimenA comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy.Association of saquinavir plasma concentrations with side effects but not with antiretroviral outcome in patients infected with protease inhibitor-susceptible human immunodeficiency virus type 1Decrease of atazanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhibitor salvage regimenLopinavir/ritonavir: appraisal of its use in HIV therapy.Atazanavir/ritonavir: a review of its use in HIV therapy.Cytochrome P450 3A inhibition by atazanavir and ritonavir, but not demography or drug formulation, influences saquinavir population pharmacokinetics in human immunodeficiency virus type 1-infected adults.A review of current literature on second-generation, sucrose-formulated, full-length recombinant factor VIII.Safety of pharmacoenhancers for HIV therapy.Daily dosing of tacrolimus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravir.Lopinavir/ritonavir pharmacokinetics, efficacy, and safety in HIV and hepatitis B or C coinfected adults without symptoms of hepatic impairment.Higher pain scores, similar opioid doses and side effects associated with antipyretic analgesics in specialised tertiary pain care.Atazanavir plasma concentrations are impaired in HIV-1-infected adults simultaneously taking a methadone oral solution in a once-daily observed therapy setting.Cross-sectional assessment of the consequences of a GTP cyclohydrolase 1 haplotype for specialized tertiary outpatient pain care.Pharmacokinetics and tolerability of a combination of indinavir, lopinavir and ritonavir in multiply pretreated HIV-1 infected adults.Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir.Impact of HIV-1 replication on immunological evolution during long-term dual-boosted protease inhibitor therapy.The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers.Significant effects of tipranavir on platelet aggregation and thromboxane B2 formation in vitro and in vivo.Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitution.Pharmacokinetics, safety and efficacy of saquinavir/ ritonavir 1,000/100 mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancy.Platelet-leucocyte adhesion markers before and after the initiation of antiretroviral therapy with HIV protease inhibitors.
P50
Q26771182-1AC61B92-2CDC-45A9-A4AD-B82CAFDB9F04Q30397265-48F5EEBF-7BDF-44EF-9CCD-938A8970E21CQ35005222-36C14C1E-E75F-4573-BE0D-62F653791FFBQ35758844-D3AA1AAD-02DA-4EB5-A82A-D89582DB224FQ35827891-C9CF9388-B88D-4B9F-8B87-AC2AE003805FQ36094901-D21B6B6B-FC86-41B9-8CBF-711AC8CE53B0Q36702983-3CA6C052-9AFA-42B7-AC46-FD61AAEA00EDQ36802358-71FFD489-80F8-4FA8-B80A-60332C362258Q37128694-4953A588-639B-4DB8-8EA2-B1F776910D84Q37274648-7CBEAED5-20DD-4FF2-A0D3-69590BE12D30Q37615950-E70BD73F-2816-44FE-9E7D-81F8BFA7C5FCQ38057371-D9186A01-FB11-47CF-84BB-27FBB0754220Q41965052-0045189E-BFC2-4C64-BF78-FE5DFCF7AADCQ42231192-70540B66-DFF1-4C49-BED0-F7C14A4DA58BQ43057561-044BE9C1-C6B7-4EC2-8254-17A9721D92ACQ43208423-FC7F51B5-081C-4C04-B229-BDB13348E956Q43256316-F3B3241A-20E1-4CCE-929F-98336B1AF112Q43500813-84771665-6D4D-410C-8780-E0E39E3891EDQ43671930-B32D283A-051D-4970-9084-B5A2565660CFQ43760953-D3C4D8FE-2603-406D-80B8-43FCD8EF8E90Q43846085-DDA316C5-AF99-4F03-B49D-E833C7AD9D55Q44343033-67AF2938-689F-4BB3-B551-D8D5462F6026Q45874020-BD0790DC-9DF9-407B-8A46-FB31922625A5Q46047802-15F58F95-E253-4BB0-BF4C-FA9845B28D07Q46132439-20392164-291C-46E3-85B5-E7C2B055538BQ46407242-C5A7CF8D-1BB0-4547-943C-64C5AD752695
P50
name
Nils von Hentig
@ast
Nils von Hentig
@en
Nils von Hentig
@es
Nils von Hentig
@fr
Nils von Hentig
@nl
type
label
Nils von Hentig
@ast
Nils von Hentig
@en
Nils von Hentig
@es
Nils von Hentig
@fr
Nils von Hentig
@nl
prefLabel
Nils von Hentig
@ast
Nils von Hentig
@en
Nils von Hentig
@es
Nils von Hentig
@fr
Nils von Hentig
@nl